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Abstract
Background: Imperfect sensitivity of interferon-c release assay (IGRA) is a potential problem to detect tuberculosis. We
made a thorough investigation of the factors that can lead to false negativity of IGRA.
Methods: We recruited 543 patients with new smear-positive pulmonary tuberculosis in Hanoi, Viet Nam. At diagnosis,
peripheral blood was collected and IGRA (QuantiFERON-TB Gold In-Tube) was performed. Clinical and epidemiological
information of the host and pathogen was collected. The test sensitivity was calculated and factors negatively influencing
IGRA results were evaluated using a logistic regression model in 504 patients with culture-confirmed pulmonary
tuberculosis.
Results: The overall sensitivity of IGRA was 92.3% (95% CI, 89.6%–94.4%). The proportions of IGRA-negative and -
indeterminate results were 4.8% (95% CI, 3.1%–7.0%) and 3.0% (95% CI, 1.7%–4.9%). Age increased by year, body mass
index ,16.0, HIV co-infection and the increased number of HLA-DRB1*0701 allele that patients bear showed significant
associations with IGRA negativity (OR=1.04 [95% CI, 1.01–1.07], 5.42 [1.48–19.79], 6.38 [1.78–22.92] and 5.09 [2.31–11.22],
respectively). HIV co-infection and the same HLA allele were also associated with indeterminate results (OR=99.59 [95% CI,
15.58–625.61] and 4.25 [1.27–14.16]).
Conclusions: Aging, emaciation, HIV co-infection and HLA genotype affected IGRA results. Assessment of these factors
might contribute to a better understanding of the assay.
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Introduction
Tuberculosis (TB) remains a disease of serious concern; one
third of the global population is infected with Mycobacterium
tuberculosis (MTB) and eight to ten million people develop the
disease every year [1]. The primary step to control TB is detecting
infection by a sensitive test.
Recently, an immunoassay that measures interferon (IFN)-c
response to MTB-specific antigens (interferon-c release assay;
IGRA) has been developed. Studies on the use of IGRA in patients
with active TB have had two purposes: (1) to evaluate performance
of IGRA in latent TB infection (LTBI) using active TB as a
surrogate, and (2) to determine whether IGRA plays a supple-
mentary role in the exclusion of active TB disease in optimal
setting [2–4].
IGRA use in diagnosis of LTBI has been established and
supported by European and American guidelines [5,6], whereas its
use has not been recommended to rule out active disease
particularly in high-burden countries, because of low sensitivity
and low negative predictive values [7,8]. Consequently, so far the
sensitivity of IGRA varies from 64% to 92% [3], but the number
of reports from high-burden countries is limited.
Imperfect sensitivity is a potential problem when using this assay
to exclude LTBI as well as active TB. Due to the lack of a gold
standard for LTBI identification, mechanisms by which IGRA
gives false-negative results in LTBI are largely unknown [2,3].
Identification and characterization of factors that lower the test
sensitivity, by using active TB patients as a surrogate for LTBI
suspects, would delineate active TB-disease specific and non-
specific mechanisms that underlie false negative results of IGRA.
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relevant factors including extent of TB lesions, malnutrition, aging,
HIV co-infection, and MTB strains. Inherent genetic variations
are also candidate factors affecting IGRA results. Among these,
polymorphism of human leukocyte antigen (HLA) is classically
known to influence T-cell immune response and determines IFN-c
concentrations after stimulation with MTB antigens [9]. In this
study, we thus attempted to investigate host- and pathogen-related
factors that may influence IGRA results obtained from more than
500 patients with active TB in Viet Nam.
Methods
Ethics statement
A written informed consent was obtained from each participant.
The study was approved by ethical committees of the Ministry of
Health, Viet Nam and National Center for Global Health and
Medicine, Japan respectively.
Study population
This study is a part of our prospective study on active TB in
Hanoi. After signing informed consents, 543 unrelated patients
with smear-positive pulmonary TB, equal to or more than 16 years
of age, and without history of TB treatment, entered this study
from July 2007 to March 2009. Information of no previous TB
treatment was based on self-declaration of patients and documents
in district TB centers.
All had sputum smear-positive TB. Solid MTB culture on
Lo ¨wenstein-Jensen media was available in 98.2% and confirmed
the diagnosis in 504 patients (92.8%). The sensitivity and risk-
factor analysis was made in these culture-confirmed pulmonary
TB cases, although clinicians diagnosed all 543 patients as active
pulmonary TB and treated them with anti-TB drugs based on the
guidelines of the national TB program. Spoligotyping was used to
distinguish MTB genotypes including Beijing strains [10]. At
diagnosis before anti-TB treatment, the peripheral blood was
drawn for testing complete blood count, HIV, IGRA and HLA
genotyping. After 2 months of treatment, IGRA was tested again.
Chest X-ray films were interpreted by two readers independently
of IGRA results.
IGRA
In this study, ELISA-based IGRA, QuantiFERON-TB Gold
In-Tube
TM (QFT-IT) (Cellestis, Victoria, Australia), was used
[11]. The algorithm and software (QuantiFERON-TB Gold
Analysis Software, version 2.50, Cellestis) provided by the
manufacturer were strictly followed for interpretation of the
results [11]. The testing procedure was carefully monitored [12]
and quality control of the test was done in each run, following the
manufacturer’s instructions. For analysis of IFN-c values higher
than 10.00 IU/ml, the truncated value (10.00 IU/ml) was used as
indicated in the current software.
HLA typing
Genomic DNA was extracted from the whole blood by using the
QIAamp
TM DNA Blood Midi Kit (QIAGEN Sciences, German-
town, MD, USA). DNA-based HLA typing was performed by
Luminex Multi-Analyte Profiling system (xMAP) with WAKFlow
HLA typing kit (Wakunaga, Hiroshima, Japan) as described [13].
Briefly, highly polymorphic exon 2 of HLA-DRB1 and -DQB1
genes were amplified. Each PCR product was hybridized with
sequence-specific oligonucleotide probes, complementary to the
allele-specific sequences.
Linkage disequilibrium analysis and binding peptide
prediction for HLA alleles
Haploview version 4.2 (Broad Institute, Cambridge, MA) was
used to calculate indicators of linkage disequilibrium, D’ and r
2,
between HLA-DRB1 and -DQB1 alleles [14,15].
To predict peptides in the protein sequence of ESAT-6, CFP10
and TB7.7 capable of binding to a given HLA-DRB1 allele in
silico, we used the ProPred database [16,17] with a threshold of
3%, a recommended setting.
Statistical analysis
Factors negatively influencing IGRA results were initially
screened by univariate analysis and then further investigated by
multivariate analysis using a polytomous logistic regression model,
with IGRA-negative and -indeterminate results as outcome
variables and factors that may be involved in host immunity and
disease as independent variables. Another logistic regression model
using a dichotomous outcome variable, non-positive (negative and
indeterminate) versus positive results, was also tested. Odd ratio
(OR) and 95% confidential interval (CI) were thus calculated.
HLA candidate alleles were initially screened by comparison of
allele frequencies between IGRA-negative and -positive groups,
and then further investigated by the logistic regression model
mentioned above.
Fisher’s exact test was used to detect associations. Bonferroni’s
correction was applied to correct multiple comparisons of
association with HLA alleles. Distribution of IFN-c values was
represented by using median with interquartile range (IQR).
When a value was higher than 10.00 IU/ml, truncated values
(10.00 IU/ml) were presented and a quantile value based on
extrapolation was supplied only as parenthetical. Wilcoxon rank-
sum test and Kruskal-Wallis test were used to compare non-
parametric distribution of two groups and more than two groups,
respectively. P value ,0.05 was considered to be statistically
significant, unless otherwise specified. Statistical analysis was
performed using Stata version 10 (StataCorp, College Station,
TX).
Results
Characteristic of the study population
Data including QFT-IT results were analyzed in 504 new
patients with culture-confirmed pulmonary TB. The median age
was 38.8, the proportion of male patients was 79.2%, and HIV
was positive in 8.7% of the cases. Body mass index (BMI) showed
that more than 50% of the patients were underweight, following
the categorization on the basis of international guidelines [18]
(table 1).
QFT-IT results
In 504 patients tested, the overall sensitivity of QFT-IT was
92.3% (95% CI, 89.6%–94.4%), but decreased to 61.4% (95% CI,
45.5%–75.6%) in HIV-infected patients (table 2). The proportions
of QFT-IT-negative and -indeterminate results were 4.8% (95%
CI, 3.1%–7.0%) and 3.0% (95% CI, 1.7%–4.9%) respectively. All
of the 15 indeterminate cases had low response to phytohaemag-
glutinin (PHA, or mitogen) and TB-Ag after subtracting Nil value
(TBAg-Nil) (0.20 [IQR, 0.04–0.34] IU/ml and 0.03 [IQR, 0.01–
0.06] IU/ml, respectively). Compared with the patients who had
test-positive results, those with negative results were significantly
older (median age: 48.9 [IQR, 33.2–62.6] vs 39.0 [IQR, 29.1–
50.6], P=0.036), and had significantly lower BMI (median BMI:
16.6 [IQR, 13.9–17.9] vs 18.3 [16.9–19.7] kg/m
2, P=0.0001)
(table not shown).
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Since QFT-IT is based on T-cell response to MTB-specific
antigenic peptides that are presented with MHC class II
molecules, we investigated the role of HLA-DRB1 and -DQB1
alleles. Among seven most common HLA-DRB1 and -DQB1
alleles tested in the population [13], the allele frequencies of HLA-
DRB1*0701 and DQB1*0201 in the test-negative group were
significantly higher than that of the positive group (P,0.0001 and
P=0.001, respectively, which remained significant after Bonfer-
roni’s correction) (table 3).
Nonrandom association between HLA-DRB1*0701 and
DQB1*0202 was tested and HLA-DRB1*0701 was found to be
in moderate linkage disequilibrium (LD) with HLA-DQB1*0201
allele (D’=0.608 and r
2=0.235) (table not shown). The TBAg-Nil
values of IFN-c in the HLA-DRB1*0701-negative/DQB1*0201-
positive group were not significantly lower than those in the both
negative group (6.65 IU/ml [IQR, 2.85–10.00 (16.06)] vs
7.76 IU/ml [IQR, 2.58–10.00 (14.87)], P=0.989), whereas the
IFN-c values in the HLA-DRB1*0701-positive/DQB1*0201-
negative group was significantly lower than those in the both
negative group (2.30 IU/ml [IQR, 1.22–4.44] vs 7.76 IU/ml
[IQR, 2.58–10.00 (14.87)], P,0.001) (table not shown).
TBAg-Nil values of all four patients with two HLA-DRB1*0701
alleles (homozygous for HLA-DRB1*0701) were below 0.35 IU/
ml or the cutoff value; three negative, one indeterminate and none
had positive results. In patients with one HLA-DRB1*0701 allele
(heterozygous for HLA-DRB1*0701), proportions of negative,
indeterminate and positive results were 9.4% (5/53), 7.6% (4/53)
and 83.0% (44/53). In patients with no HLA-DRB1*0701 alleles
(homozygous for non-HLA-DRB1*0701), the proportions were
3.6% (16/447), 2.2% (10/447) and 94.2% (421/447) respectively.
Overall distribution of QFT-IT results was significantly different
among HLA-DRB1*0701 genotypes (P,0.0001). The effect of
two HLA-DRB1*0701 alleles on QFT-IT negativity was signifi-
cant (3/4 vs 16/447, P=0.0002), whereas the effect of one HLA-
DRB1*0701 allele on QFT-IT negativity was weaker than that of
two HLA-DRB1*0701 alleles (5/53 vs 3/4, P=0.007) and did not
reach significant levels (5/53 vs 16/447, P=0.06) when ‘‘no
alleles’’ was regarded as a category for reference purposes.
Distribution of IFN-c values may provide information about the
mechanism by which false negative results are observed. We
reviewed the relationship between IFN-c values and HLA-
DRB1*0701 genotypes (Figure 1). HLA-DRB1*0701 genotype
significantly affected TB-Ag specific IFN-c response (TBAg-Nil)
(P,0.001): The IFN-c values in patients with two HLA-
DRB1*0701 alleles (homozygous for HLA-DRB1*0701) were
significantly lower than those in patients with one HLA-
DRB1*0701 allele (heterozygous for HLA-DRB1*0701)
(0.15 IU/ml [IQR, 0.06–0.26] vs 1.91 IU/ml [IQR, 0.65–4.21],
P=0.008). As a reference, the median of IFN-c values in patients
who did not bear any HLA-DRB1*0701 alleles was 7.59 IU/ml
[IQR, 2.63–10.00 (14.92)].
No association was clinically observed between HLA-
DRB1*0701-containing genotype and disease severity assessed
by either cavity or infiltrate on CXR respectively (data not shown).
QFT-IT test was performed again after two months of anti-TB
treatment in 17 out of 19 HIV-negative patients with QFT-IT-
negative results. All 7 patients who carried one or two HLA-
DRB1*0701 alleles showed negative results again, whereas it
remained negative only in 6 out of 10 patients without carrying the
HLA allele, though this difference did not reach significant levels
(P=0.103).
Analysis of 51 HLA-DR alleles registered on the ProPred
database revealed that the average number of epitopes predicted
in the overall amino acid sequences of ESAT-6 (95 amino acids),
Table 1. Characteristics of patients with smear-positive/
culture-positive pulmonary tuberculosis (n=504).
Number %
Age (years old) (median, IQR) (38.8, 29.2–50.8)
Sex Male 399 79.2
Female 105 20.8
Body mass index ,16.0 77 15.3
16.0–18.4 206 40.9
18.5–24.9 218 43.2
$25.0 3 0.6
Smoking habit Smoker 199 39.5
Ex-smoker 136 27.0
Non-smoker 168 33.3
No answer 1 0.2
Underlying disease other than HIV* None 435 86.3
One 61 12.1
More than one 8 1.6
HIV status Positive 44 8.7
Negative 459 91.1
Not available 1 0.2
Lymphocyte count $1,000/mm3 442 87.7
,1,000/mm3 60 11.9
Not available 2 0.4
IQR: inter-quartile range, HIV: human immunodeficiency virus; TB: Tuberculosis;
*Includes diabetes mellitus, gastrectomy, gastric ulcer, renal failure and gout
(hyperuricemia).
doi:10.1371/journal.pone.0023806.t001
Table 2. QFT-IT results and HIV status in smear-positive/culture-positive pulmonary TB patients.
Positive Negative Indeterminate P*
n % (95% CI) n % (95% CI) n % (95% CI)
All (n=504) 465 92.3 (89.6–94.4) 24 4.8 (3.1–7.0) 15 3.0 (1.7–4.9)
HIV positive (n=44) 27 61.4 (45.5–75.6) 5 11.4 (3.8–24.6) 12 27.3 (15.0–42.8) ,0.001
HIV negative (n=459) 437 95.2 (92.8–97.0) 19 4.1 (2.5–6.4) 3 0.7 (0.1–1.9)
QFT-IT: QuantiFERON-TB Gold In-Tube; HIV: human immunodeficiency virus; TB: Tuberculosis; CI: Confidence interval.
*Comparison was made between HIV-positive and HIV-negative groups.
doi:10.1371/journal.pone.0023806.t002
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Allele name Number of alleles (% [95%CI]) P*
Total IGRA positive IGRA-negative
2n{=1008 2n=930 2n=48
HLA-DRB1
1202 337 (33.4 [30.5–36.4]) 318 (34.2 [31.1–37.3]) 11 (22.9 [12.0–37.3]) 0.119
0901 129 (12.8 [10.8–15.0]) 119 (12.8 [10.7–15.1]) 6 (12.5 [4.7–25.2]) .0.999
0701 61 (6.1 [4.7–7.7]) 44 (4.7 [3.5–6.3]) 11 (22.9 [12.0–37.3]) ,0.0001
1502 59 (5.9 [4.5–7.5]) 53 (5.7 [4.3–7.4]) 5 (10.4 [3.5–22.7]) 0.198
0301 54 (5.4 [4.0–6.9]) 49 (5.3 [3.9–6.9]) 4 (8.3 [2.3–20.0]) 0.324
0803 53 (5.3 [4.0–6.8]) 51 (5.5 [4.1–7.1]) 0 (0.0 [0.0–7.4]) 0.170
1001 51 (5.1 [3.8–6.6]) 49 (5.3 [3.9–6.9]) 2 (4.2 [0.5–14.3]) .0.999
others 264 (26.2 [23.5–29.0]) 247 (26.6 [23.7–29.5]) 9 (18.8 [8.9–32.6]) 0.312
HLA-DQB1
0301 383 (38.0 [35.0–41.1]) 361 (38.8 [35.7–42.0]) 12 (25.0 [13.6–39.6]) 0.067
0303 152 (15.1 [12.9–17.4]) 138 (14.8 [12.6–17.3]) 9 (18.8 [8.9–32.6]) 0.414
0501 94 (9.3 [7.6–11.3]) 87 (9.4 [7.6–11.4]) 6 (12.5 [4.7–25.2]) 0.448
0201 92 (9.1 [7.4–11.1]) 74 (8.0 [6.3–9.9]) 12 (25.0 [13.6–39.6]) 0.001
0502 81 (8.0 [6.4–9.9]) 76 (8.2 [6.5–10.1]) 3 (6.3 [1.3–17.2]) .0.999
0601 70 (6.9 [5.5–8.7]) 68 (7.3 [5.7–9.2]) 0 (0.0 [0.0–7.4]) 0.072
0401 42 (4.2 [3.0–5.6]) 40 (4.3 [3.1–5.8]) 1 (2.1 [0.1–11.1]) 0.717
others 94 (9.3 [7.6–11.3]) 86 (9.2 [7.5–11.3]) 5 (10.4 [3.5–22.7]) 0.797
*Comparison was made between QFT-IT-positive and -negative groups. After Bonferroni’s correction, P ,0.006 was statistically significant, considering the number of
comparisons.
{Allele number is shown.
HLA: Human leukocyte antigen; QFT-IT: QuantiFERON-TB Gold In-Tube.
doi:10.1371/journal.pone.0023806.t003
Figure 1. IFN-c response to TB antigens stratified by HLA-DRB1*0701 genotypes in smear-positive/culture-positive pulmonary TB
patients (n=504). HLA-DRB1*0701 genotype significantly affected TB-Ag specific IFN-c response (TBAg-Nil) (P,0.001). IFN: Interferon; TB:
Tuberculosis; HLA: Human leukocyte antigen; Ag: Antigen.
doi:10.1371/journal.pone.0023806.g001
False-Negative Results of IGRA
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23806CFP10 (100 amino acids) and TB7.7 p4 (18 amino acids) to bind a
given allele was median of 4 with IQR in 3 to 5, but the number of
epitopes predicted for HLA-DRB1*0701 was only one (data not
shown).
Univariate analysis
Host factors including age, sex, BMI, underlying diseases,
disease status, and inherent characteristics of pathogen were
analyzed. The number of HLA-DRB1*0701 alleles carried by the
patients appeared to be associated with the test-negative results.
For this reason, this variable was also included in the statistical
model.
In univariate analysis, increased age by year, BMI,16.0, HIV
co-infection and the number of HLA-DRB1*0701 alleles carried
by patients showed significant associations with the negative results
(OR=1.04 [95%CI, 1.01–1.06], 7.27 [95%CI, 2.17–24.38], 4.26
[95%CI, 1.48–12.28], and 5.47 [95%CI, 2.58–11.61] respectively)
(table 4). Sex, underlying diseases other than HIV infection,
hospitalization, presence of infiltrates in more than half of the lung
field and cavitary lesions on chest X-ray (CXR) did not show
significant associations (data not shown). Beijing MTB strains were
less frequently seen in the test-negative group (OR=0.29 [95%
CI, 0.11–0.76]). Multi-drug resistant (MDR)-TB strains showed no
association with IGRA-negative results.
With QFT-IT indeterminate results, HIV co-infection, low
lymphocyte count, MDR and the number of HLA-DRB1*0701
alleles showed significant associations (OR=64.74 [95% CI,
17.23–243.20], 26.19 [95% CI, 8.00–85.72], 6.37 [95% CI, 1.64–
24.68] and 4.66 [95% CI, 1.83–11.88], respectively).
Multivariate analysis
Age, sex, BMI, HIV status, lymphocyte count, and the number
of HLA-DRB1*0701 alleles were put into the initial model for
multivariate analysis. MTB strain and MDR-TB were not put
together into this model because of the considerable number of
missing values but analyzed separately as described later. In the
final model, increased age by year, BMI ,16.0, HIV co-infection
and the number of HLA-DRB1*0701 alleles showed significant
association with QFT-IT negativity (OR=1.04 [95% CI, 1.01–
1.07], 5.42 [95% CI, 1.48–19.79], 6.38 [95% CI, 1.78–22.92] and
5.09 [95% CI, 2.31–11.22] respectively) (table 5).
HIV co-infection and the number of HLA-DRB1*0701 alleles
were also significantly associated with QFT-IT indeterminate
results (OR=99.59 [95% CI, 15.85–625.61] and 4.25 [95% CI,
1.27–14.16] respectively).
When non-positive (negative and indeterminate) results of QFT-
IT were compared with positive results, increased age by year,
BMI ,16.0, HIV co-infection and the number of HLA-
DRB1*0701 alleles showed similarly high odds ratios (Table S1).
Bacterial characteristics and IFN-c responses
Among 488 patients for whom information of QFT-IT and
MTB strains were both available, concentrations of IFN-c
responding to MTB-specific antigens were neither different
between patient groups with Beijing and non-Beijing MTB strains
(6.92 IU/ml [2.19–10.00 (14.42)] vs 6.00 IU/ml [2.12–10.00
(14.54)]) nor between patient groups with MDR-TB and non-
MDR-TB strains (4.19 IU/ml [0.62–10.00 (15.72)] vs 6.57 IU/ml
[2.19–10.00 (14.47)]) (table not shown).
Discussion
We calculated the test sensitivity of ELISA-based IGRA among
active TB patients in Viet Nam and made an extensive analysis of
the factors associated with the false-negative results, which include
increased age by year, extremely low BMI, HIV co-infection, and
the number of HLA-DRB1*0701 alleles carried by the patients.
Aging is known as a risk factor for false-negative results [19,20].
Kobashi et al. [19] reports that the positive rate for both ESAT-6
and CFP-10 antigens of QuantiFERON TB-2G tested in the
patients $80 years old is significantly lower than that in younger
patients. In another study conducted by Liao et al. [20], using
ELISPOT assay, increasing age is associated with false-negative
results. HIV co-infection was associated with indeterminate results
as well as false-negative results, presumably due to strong
suppression of mitogenic response [21].
Severe wasting disease or malnutrition causes unhealthy
emaciation with extremely low BMI, debilitating the patients
and also suppressing systemic immune response [22]. In our study,
BMI ,16.0 kg/m
2, was significantly associated with IGRA
negativity whereas moderate and mild underweight (BMI from
16.0 to less than 18.5) were not. The proportion of BMI ,18.5 in
the general population in Hanoi was only 13.3% [23], indicating
that very low BMI in our study population is associated with active
TB disease. However, it is not known whether this emaciation is
observed mainly as a result of the current wasting disease or partly
a risk factor for disease development.
In this study, we newly demonstrated that a particular MHC
class II allele, HLA-DRB1*0701, was strongly associated with low
TBAg-Nil values observed in indeterminate and negative results.
HLA-DRB1*0701-positive/DQB1*0201-negative group but not
HLA-DRB1*0701-negative/DQB1*0201-positive group sup-
pressed the IFN-c response, which suggests that HLA-
DQB1*0701, but not HLA-DQB1*0201 has a primary role.
The negative effect of HLA-DRB1*0701 on the IFN-c values
appeared to intensify in proportion to the number of HLA-
DRB1*0701 alleles. The association between the increased
number of the HLA alleles and QFT-IT negative results was
demonstrated by the analysis using a logistic regression model.
After two months of anti-TB treatment, all of our IGRA-
negative patients bearing the HLA allele continued to show
negative IGRA results. There was no significant association
between the extent of disease on CXR and the HLA-DRB1*0701
genotype (data not shown), suggesting that the allele does not seem
to affect the assay results through modulation of disease severity. In
silico analysis suggested the low affinity of HLA-DRB1*0701 in
binding with both ESAT-6 and CFP10 epitopes, and possibly
failing to present them to T-cells for initiation of Th1 immune
response efficiently [24].
Considering the low frequency of HLA-DRB1*0701 in the
population tested, this finding may not have major clinical
implications. However, we should bear in mind that negative
QFT-IT results might be experienced in TB-infected individuals
within a certain genetic background of the host even without
apparent cause of immunodeficiency. In addition, it might be
necessary to be investigated carefully in Southwestern Europe,
North Africa, East Sub-Saharan Africa, West and South Asia
among others, where high frequency (.15%) of the allele has been
reported [25] and more than 2% of the people are supposed to
possess this allele as homozygote. Further clinical investigations
about HLA type and IGRA and in vitro experiments would
contribute to a better understanding of IGRA performance in
general and of QFT-IT in particular.
In analogy with negative results of tuberculin skin testing
occasionally obtained in severe TB disease [26], IGRA-false-
negative results may be caused by inefficient activation of antigen-
specific CD4 T-cells [27], based on poorly-defined regulatory
mechanism [28,29]. T-cell trafficking to the active TB sites or
False-Negative Results of IGRA
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response in circulating blood [28]. However, this mechanism may
not explain a major part of false-negative results in our study
because the extent of infiltrates or presence of cavity on CXR did
not show significant effects on the assay results.
Beijing MTB strains have spread rapidly in Asia and previous
reports show that these are more adapted to the human body
evading immune mechanism than others [30]. Although an
inverse association was apparently observed between isolation of
Beijing strains and IGRA negativity in our study, it may be
attributed to unknown factors we could not access, since we made
no demonstration of difference in TBAg-induced IFN-c levels
between Beijing and non-Beijing strains.
The overall sensitivity of QFT-IT in our population was
considerably high among high TB burden countries from Cape
Town in South Africa, the Gambia, Zambia, India, and some
other countries [3]. This seems to be due to the lower proportion
of false-negative results in our study (4.8%) compared to (9.1% to
29%) in those studies. Several possible reasons for the interpre-
tation of this point derive from our findings and others [19,20]:
low proportion of underlying diseases including HIV, very few
patients receiving immunosuppressive therapy, and recruitment of
only new patients with sputum smear-confirmed pulmonary TB.
Our study had some limitations. Firstly, a clinical laboratory to
measure CD4 count was not accessible during the study period,
although CD4 count is an important parameter for this assessment
[31]. Decrease in total lymphocyte count was used as a surrogate
marker. Secondly, only smear-positive patients without previous
treatment have been recruited, which may not allow us to
generalize our results to all types of TB. Thirdly, further
investigation is necessary to know whether all of the factors
identified here affect results of ELISPOT-based IGRA as well.
Lastly, the number of patients showing negative results was rather
small despite the large number of recruited patients in our study.
Table 4. Univariate analysis using polytomous logistic regression model for factors associated with QFT-IT-negative and -
indeterminate results (n=503).
QFT-IT-negative results QFT-IT-indeterminate results
Proportion (%) OR* 95% CI Proportion (%) OR* 95% CI
Sex Male 21/398 (5.3) 1.00 13/398 (3.3) 1.00
Female 3/105 (2.9) 0.52 0.15–1.78 2/105 (1.9) 0.56 0.12–2.52
Age (years) 1.04 1.01–1.06 0.98 0.94–1.02
BMI 18.5–24.9 4/217 (1.8) 1.00 3/217 (1.4) 1.00
,16.0 9/77 (11.7) 7.27 2.17–24.38 3/77 (3.9) 3.23 0.64–16.40
16.0–18.5 11/206 (5.3) 3.10 0.97–9.92 9/206 (4.4) 3.39 0.90–12.70
$25.0 0/3 (0.0) NA NA 0/3 (0.0) NA NA
Underlying condition None 20/434 (4.6) 1.00 14/434 (3.2) 1.00
One 4/61 (6.6) 1.43 0.47–4.34 1/61 (1.6) 0.51 0.07–3.96
More than one 0/8 (0.0) NA NA 0/8 (0.0) NA NA
HIV status Negative 19/459 (4.1) 1.00 3/459 (0.7) 1.00
Positive 5/44 (11.4) 4.26 1.48–12.28 12/44 (27.3) 64.74 17.23–243.20
Lymphocyte count (cells/mm3) $1,000 19/441 (4.3) 1.00 4/441 (0.9) 1.00
,1,000 5/60 (8.3) 2.51 0.89–7.04 11/60 (18.3) 26.19 8.00–85.72
Direct smear result Scanty 3/65 (4.6) 1.00 3/65 (4.6) 1.00
1+ and more 21/438 (4.8) 1.02 0.30–3.52 12/438 (2.7) 0.58 0.16–2.13
Cavity on CXR No 6/145 (4.1) 1.00 9/145 (6.2) 1.00
Yes 16/327 (4.9) 1.13 0.43–2.95 4/327 (1.2) 0.19 0.06–0.62
Infiltrate in .3 lung zones No 15/391 (3.8) 1.00 12/391 (3.1) 1.00
Yes 7/83 (8.4) 2.26 0.89–5.75 1/83 (1.2) 0.40 0.05–3.16
Hospitalization No 17/375 (4.5) 1.00 9/375 (2.4) 1.00
To TB ward 5/104 (4.8) 1.10 0.40–3.07 6/104 (5.8) 2.50 0.87–7.21
To ER 2/24 (8.3) 1.87 0.41–8.59 0/24 (0.0) NA NA
HLA-DRB1*0701 (the number of
alleles)
5.47{ 2.58–11.61 4.66{ 1.83–11.88
MDR No 21/466 (4.5) 1.00 12/466 (2.6) 1.00
Yes 2/22 (9.1) 2.43 0.53–11.19 3/22 (13.6) 6.37 1.64–24.68
MTB strain Non-Beijing 17/229 (7.4) 1.00 8/229 (3.5) 1.00
Beijing 6/259 (2.3) 0.29 0.11–0.76 7/259 (2.7) 0.73 0.26–2.03
QFT-IT: QuantiFERON-TB Gold In-Tube; BMI: Body mass index; CXR: Chest X-ray; MDR: Multi drug resistance; TB: Tuberculosis; ER: Emergency room; MTB: Mycobacterium
tuberculosis; CI: Confidence interval; NA: Not available.
*OR: Multinomial odds ratio, also known as relative risk ratio, that is obtained by exponentiating the logit coefficient.
{OR per unit change in the number of alleles: Distribution of QFT-IT results and the number of HLA-DRB1*0701 alleles was shown in the text.
doi:10.1371/journal.pone.0023806.t004
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However, we were able to identify a novel host genetic factor,
HLA*DRB1-0701. If well-known factors such as HIV co-infection
were predominant in the studied population, individuals bearing
the host genetic factor might have a chance of having those
extrinsic factors together and it might be difficult to demonstrate
that their genetic difference is a primary cause of false negativity.
Although some of the factors associated with IGRA-negative
results have been proposed or even studied adopting a piecemeal
method [2,3], the strong point of our study is that effects of all
factors have been evaluated simultaneously by using appropriate
statistical models, which provided a comprehensive insight into
this area of interest.
In conclusion, we identified a specific HLA class II allele and
characterized a variety of factors that possibly lead to false
negativity of IGRA in active pulmonary TB. Detailed investigation
of these unfavorable factors is necessary and would help to
understand further the performance of the assay.
Supporting Information
Table S1 Univariate and multivariate analysis using
logistic regression model for factors associated with
QFT-IT non-positive (negative and indeterminate) re-
sults (n=503).
(DOC)
Acknowledgments
The authors would like to thank Dr. Nguyen Phuong Hoang, Dr. Bui Thi
Nguyet, Ms. Vu Thi Xuan Thu, Dr. Pham Tuan Phuong, Dr. Pham Thu
Anh (Hanoi Lung Hospital), Dr. Tran Thi Bich Thuy (National Lung
Hospital), Dr. Phan Thi Minh Ngoc, Ms. Nguyen Thi Ha (NCGM-BMH
Medical Collaboration Center) and all healthcare staff of relevant district
TB centers for supporting site implementation. The authors thank Dr.
Masaki Matsushita (Wakunaga Pharmaceutical Co., Ltd) for technical
support of HLA typing. The authors thank Kazuko Tanabe D.V.M. and
Mr. John Crosskey for their critical reading of this manuscript.
Author Contributions
Conceived and designed the experiments: NTLH LTL N. Kobayashi SS
PHT N. Keicho. Performed the experiments: NTLH LTL PHT LTH
DBT MH IM NVH. Analyzed the data: NTLH TS N. Keicho.
Contributed reagents/materials/analysis tools: KH NH N. Keicho. Wrote
the paper: NTLH N. Keicho.
References
1. WHO Global Tuberculosis Control. Geneva: World Health Organization.
Available: http://whqlibdoc.who.int/publications/2010/9789241564069_eng.
pdf. Accessed 2011 July 27.
2. Pai M, Menzies D (2007) Interferon-a ˜ release assays: what is their role in the
diagnosis of active tuberculosis? Clin Infect Dis 44: 74–77.
3. Dheda K, van Zyl Smit R, Badri M, Pai M (2009) T-cell interferon-c release
assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-
burden vs. low-burden settings. Curr Opin Pulm Med 15: 188–200.
4. Diel R, Loddenkemper R, Nienhaus A (2010) Evidence-based comparison of
commercial interferon-c release assays for detecting active TB: a metaanalysis.
Chest 137: 952–968.
5. European Centre for Disease Prevention and Control (2011) Use of interferon-
gamma release assays in support of TB diagnosis. Stockholm: ECDC. Available:
http://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf.
Accessed 2011 May 4.
6. Centers for Disease Control and Prevention (2010) Updated Guidelines for
Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis
Infection — United States. MMWR 2010; 59. Available: http://www.cdc.gov/
mmwr/pdf/rr/rr5905.pdf. Accessed 2011 March 31.
7. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, et al. (2011) Interferon-c
release assays for the diagnosis of active tuberculosis: a systematic review and
meta-analysis. Eur Respir J 37: 100–111.
8. Ling DI, Pai M, Davids V, Brunet L, Lenders L, et al. (2011) Are interferon-
{gamma} release assays useful for active tuberculosis in a high-burden setting?
Eur Respir J. In press.
9. Mustafa AS, Oftung F, Amoudy HA, Madi NM, Abal AT, et al. (2000) Multiple
epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by
antigen-specific human T cell lines. Clin Infect Dis 30: S201–205.
10. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, et al. (2006)
Mycobacterium tuberculosis complex genetic diversity: mining the fourth interna-
tional spoligotyping database (SpolDB4) for classification, population genetics
and epidemiology. BMC Microbiol 6: 23.
11. Cellestis website. QuantiFERONH-TB Gold In-Tube. Available: http://www.
cellestis.com/IRM/Content/usa/qftproducts_tbgoldintube.html. Accessed 2011
July 27.
12. Hang NT, Ishizuka N, Keicho N, Hong LT, Tam DB, et al. (2009) Quality
assessment of an interferon-c release assay for tuberculosis infection in a
resource-limited setting. BMC Infect Dis 9: 66.
Table 5. Multivariate analysis using polytomous logistic regression model for factors associated with QFT-IT-negative and -
indeterminate results (n=503).
QFT-IT-negative results QFT-IT-indeterminate results
Proportion (%) OR* 95% CI Proportion (%) OR* 95% CI
Age (years) 1.04 1.01–1.07 1.04 0.97–1.11
BMI 18.5–24.9 4/217 (1.8) 1.00 3/217 (1.4) 1.00
,16.0 9/77 (11.7) 5.42 1.48–19.79 3/77 (3.9) 1.82 0.29–11.18
16.0–18.5 11/206 (5.3) 2.65 0.79–8.85 9/206 (4.4) 1.92 0.43–8.48
$25.0 0/3 (0.0) NA NA 0/3 (0.0) NA NA
HIV status Negative 19/459 (4.1) 1.00 3/459 (0.7) 1.00
Positive 5/44 (11.4) 6.38 1.78–22.92 12/44 (27.3) 99.59 15.85–625.61
HLA-DRB1*0701 (the number of
alleles)
5.09{ 2.31–11.22 4.25{ 1.27–14.16
QFT-IT: QuantiFERON-TB Gold In-Tube; BMI: Body mass index; HIV: human immunodeficiency virus; CI: Confidence interval; NA: Not available.
*OR: Multinomial odds ratio, also known as relative risk ratio, that is obtained by exponentiating the logit coefficient.
{OR per unit change in the number of alleles: Distribution of QFT-IT results and the number of HLA-DRB1*0701 alleles was shown in the text.
doi:10.1371/journal.pone.0023806.t005
False-Negative Results of IGRA
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e2380613. Hoa BK, Hang NT, Kashiwase K, Ohashi J, Lien LT, et al. (2008) HLA-A, -B,
-C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in
Vietnam. Tissue Antigens 71: 127–134.
14. Broad Institute website.Haploview. Available: http://www.broadinstitute.org/
scientific-community/science/programs/medical-and-population-genetics/hap
loview/haploview. Accessed 2011 July 27.
15. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
16. Bioinformatics Center IMTECH website. Propred. MHC Class-II Binding
Peptide Prediction Server. Available: http://www.imtech.res.in/raghava/
propred. Accessed 2011 July 27.
17. Singh H, Raghava GP (2001) ProPred: prediction of HLA-DR binding sites.
Bioinformatics 17: 1236–1237.
18. WHO Expert Consultation (2004) Appropriate body-mass index for Asian
populations and its implications for policy and intervention strategies. Lancet
363: 157–163.
19. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, et al. (2008)
Clinical utility of the QuantiFERON TB-2G test for elderly patients with active
tuberculosis. Chest 133: 1196–1202.
20. Liao CH, Lai CC, Tan CK, Chou CH, Hsu HL, Tasi TH, et al. (2009) False-
negative results by enzyme-linked immunospot assay for interferon-gamma
among patients with culture-confirmed tuberculosis. J Infect 59: 421–423.
21. Syed Ahamed Kabeer B, Sikhamani R, Swaminathan S, Perumal V,
Paramasivam P, et al. (2009) Role of interferon c release assay in active TB
diagnosis among HIV infected individuals. PLoS One 4: e5718.
22. Schluger NW, Rom WN (1998) The host immune response to tuberculosis.
Am J Respir Crit Care Med 157: 679–691.
23. Walls HL, Peeters A, Son PT, Quang NN, Hoai NT, Loi do D, et al. (2009)
Prevalence of underweight, overweight and obesity in urban Hanoi, Vietnam.
Asia Pac J Clin Nutr 18: 234–239.
24. Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, et al.
(2000) Antigenic equivalence of human T-cell responses to Mycobacterium
tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate
protein 10 and to mixtures of synthetic peptides. Infect Immun 68: 3314–3321.
25. dbMHC IHWG Projects website. Anthropology. Class II Allele Frequencies.
Available: http://www.ncbi.nlm.nih.gov/projects/gv/mhc/ihwg.cgi?cmd=pa-
ge&page=AnthroMain. Accessed 2011 July 27.
26. Diagnostic Standards and Classification of Tuberculosis in Adults and Children
(2000) Am J Respir Crit Care Med 161: 1376–1395.
27. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, et al.
(2001) Direct ex vivo analysis of antigen-specific IFN-a ˜-secreting CD4 T cells in
Mycobacterium tuberculosis-infected individuals: associations with clinical disease
state and effect of treatment. J Immunol 167: 5217–5225.
28. Jo EK, Park JK, Dockrell HM (2003) Dynamics of cytokine generation in
patients with active pulmonary tuberculosis. Curr Opin Infect Dis 16: 205–210.
29. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y (2010) The
immunology of tuberculosis: from bench to bedside. Respirology 15: 433–450.
30. Parwati I, van Crevel R, van Soolingen D (2010) Possible underlying
mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing
genotype strains. Lancet Infect Dis 10: 103–111.
31. Lugos MD, Adetifa IM, Donkor S, Hill PC, Adegbola RA, et al. (2009)
Evaluation of the contribution of major T cell subsets to IFN-gamma production
in TB infection by ELISPOT. Immunol Invest 38: 341–349.
False-Negative Results of IGRA
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23806